{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T03:34:50Z","timestamp":1781667290761,"version":"3.54.5"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA233576"],"award-info":[{"award-number":["CA233576"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-83740-6","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T02:41:00Z","timestamp":1735872060000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Constitutive activation of the Src-family kinases Fgr and Hck enhances the tumor burden of acute myeloid leukemia cells in immunocompromised mice"],"prefix":"10.1038","volume":"15","author":[{"given":"Sherry T.","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Gonzalez-Areizaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Smithgall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"83740_CR1","doi-asserted-by":"publisher","first-page":"e89560","DOI":"10.1371\/journal.pone.0089560","volume":"9","author":"H Janke","year":"2014","unstructured":"Janke, H. et al. Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia. PLoS ONE 9, e89560 (2014).","journal-title":"PLoS ONE"},{"key":"83740_CR2","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nature11016","volume":"485","author":"CC Smith","year":"2012","unstructured":"Smith, C. C. et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485, 260\u2013263 (2012).","journal-title":"Nature"},{"key":"83740_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1097-2765(03)00505-7","volume":"13","author":"J Griffith","year":"2004","unstructured":"Griffith, J. et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol. Cell 13, 169\u2013178 (2004).","journal-title":"Mol. Cell"},{"key":"83740_CR4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s11899-014-0203-8","volume":"9","author":"A Sudhindra","year":"2014","unstructured":"Sudhindra, A. & Smith, C. C. FLT3 inhibitors in AML: are we there yet?. Curr. Hematol. Malig. Rep. 9, 174\u2013185 (2014).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"83740_CR5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1158\/2159-8290.CD-15-0060","volume":"5","author":"CC Smith","year":"2015","unstructured":"Smith, C. C. et al. Characterizing and overriding the structural mechanism of the Quizartinib-resistant FLT3 \u201cGatekeeper\u201d F691L mutation with PLX3397. Cancer Discov. 5, 668\u2013679 (2015).","journal-title":"Cancer Discov."},{"key":"83740_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.critrevonc.2019.06.011","volume":"141","author":"TM Weis","year":"2019","unstructured":"Weis, T. M., Marini, B. L., Bixby, D. L. & Perissinotti, A. J. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. Crit. Rev. Oncol. Hematol. 141, 125\u2013138 (2019).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"83740_CR7","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood-2007-04-082099","volume":"111","author":"SC Dos","year":"2008","unstructured":"Dos, S. C. et al. A critical role for Lyn in acute myeloid leukemia. Blood 111, 2269\u20132279 (2008).","journal-title":"Blood"},{"key":"83740_CR8","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1182\/blood-2012-11-466425","volume":"122","author":"C Dos Santos","year":"2013","unstructured":"Dos Santos, C. et al. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. Blood 122, 1900\u20131913 (2013).","journal-title":"Blood"},{"key":"83740_CR9","doi-asserted-by":"publisher","first-page":"e0225887","DOI":"10.1371\/journal.pone.0225887","volume":"14","author":"RK Patel","year":"2019","unstructured":"Patel, R. K. et al. Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance. PLoS One 14, e0225887 (2019).","journal-title":"PLoS One"},{"key":"83740_CR10","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.2174\/0929867322666150209152057","volume":"22","author":"F Musumeci","year":"2015","unstructured":"Musumeci, F. et al. Hck inhibitors as potential therapeutic agents in cancer and HIV infection. Curr. Med. Chem. 22, 1540\u20131564 (2015).","journal-title":"Curr. Med. Chem."},{"key":"83740_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ejcb.2008.03.008","volume":"87","author":"R Guiet","year":"2008","unstructured":"Guiet, R. et al. Hematopoietic cell kinase (Hck) isoforms and phagocyte duties - from signaling and actin reorganization to migration and phagocytosis. Eur. J. Cell Biol. 87, 527\u2013542 (2008).","journal-title":"Eur. J. Cell Biol."},{"key":"83740_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1101\/gad.8.4.387","volume":"8","author":"CA Lowell","year":"1994","unstructured":"Lowell, C. A., Soriano, P. & Varmus, H. E. Functional overlap in the src gene family: Inactivation of hck and fgr impairs natural immunity. Genes Dev. 8, 387\u2013398 (1994).","journal-title":"Genes Dev."},{"key":"83740_CR13","doi-asserted-by":"publisher","first-page":"181ra152","DOI":"10.1126\/scitranslmed.3004387","volume":"5","author":"Y Saito","year":"2013","unstructured":"Saito, Y. et al. A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo. Sci. Transl. Med. 5, 181ra152 (2013).","journal-title":"Sci. Transl. Med."},{"key":"83740_CR14","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.1016\/j.bmcl.2017.10.012","volume":"27","author":"Y Koda","year":"2017","unstructured":"Koda, Y. et al. Identification of pyrrolo[2,3-d]pyrimidines as potent HCK and FLT3-ITD dual inhibitors. Bioorg. Med. Chem. Lett 27, 4994\u20134998 (2017).","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"83740_CR15","doi-asserted-by":"crossref","unstructured":"Shen, K. et al. The Src family kinase Fgr is a transforming oncoprotein that functions independently of SH3-SH2 domain regulation. Sci. Signal 11 (2018).","DOI":"10.1126\/scisignal.aat5916"},{"key":"83740_CR16","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1021\/acschembio.8b00154","volume":"13","author":"MC Weir","year":"2018","unstructured":"Weir, M. C. et al. Selective inhibition of the myeloid Src-family kinase Fgr potently suppresses AML cell growth in vitro and in vivo. ACS Chem. Biol 13, 1551\u20131559 (2018).","journal-title":"ACS Chem. Biol"},{"key":"83740_CR17","first-page":"117","volume":"9","author":"X Zhao","year":"2002","unstructured":"Zhao, X., Ghaffari, S., Lodish, H., Malashkevich, V. N. & Kim, P. S. Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat. Struct. Biol 9, 117\u2013120 (2002).","journal-title":"Nat. Struct. Biol"},{"key":"83740_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/jcp.1041400219","volume":"140","author":"T Kitamura","year":"1989","unstructured":"Kitamura, T. et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3 or erythropoietin. J. Cell. Physiol 140, 323\u2013334 (1989).","journal-title":"J. Cell. Physiol"},{"key":"83740_CR19","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.1074\/jbc.M112.431312","volume":"288","author":"S Panjarian","year":"2013","unstructured":"Panjarian, S. et al. Enhanced SH3\/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitors. J. Biol. Chem. 288, 6116\u20136129 (2013).","journal-title":"J. Biol. Chem."},{"key":"83740_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrm1280","volume":"5","author":"O Hantschel","year":"2004","unstructured":"Hantschel, O. & Superti-Furga, G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat. Rev. Mol. Cell Biol 5, 33\u201344 (2004).","journal-title":"Nat. Rev. Mol. Cell Biol"},{"key":"83740_CR21","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.1074\/jbc.R112.438382","volume":"288","author":"S Panjarian","year":"2013","unstructured":"Panjarian, S., Iacob, R. E., Chen, S., Engen, J. R. & Smithgall, T. E. Structure and dynamic regulation of Abl kinases. J. Biol. Chem. 288, 5443\u20135450 (2013).","journal-title":"J. Biol. Chem."},{"key":"83740_CR22","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1007\/s00018-008-8122-2","volume":"65","author":"JR Engen","year":"2008","unstructured":"Engen, J. R. et al. Structure and dynamic regulation of Src-family kinases. Cell Mol. Life Sci. 65, 3058\u20133073 (2008).","journal-title":"Cell Mol. Life Sci."},{"key":"83740_CR23","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.str.2022.08.008","volume":"30","author":"S Du","year":"2022","unstructured":"Du, S. et al. ATP-site inhibitors induce unique conformations of the acute myeloid leukemia-associated Src-family kinase, Fgr. Structure 30, 1508-1517 e1503 (2022).","journal-title":"Structure"},{"key":"83740_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1097-2765(00)80356-1","volume":"3","author":"W Xu","year":"1999","unstructured":"Xu, W., Doshi, A., Lei, M., Eck, M. J. & Harrison, S. C. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cell 3, 629\u2013638 (1999).","journal-title":"Mol. Cell"},{"key":"83740_CR25","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/nsmb.1486","volume":"15","author":"M Azam","year":"2008","unstructured":"Azam, M., Seeliger, M. A., Gray, N. S., Kuriyan, J. & Daley, G. Q. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat. Struct. Mol. Biol. 15, 1109\u20131118 (2008).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"83740_CR26","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S1097-2765(00)80357-3","volume":"3","author":"T Schindler","year":"1999","unstructured":"Schindler, T. et al. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell 3, 639\u2013648 (1999).","journal-title":"Mol. Cell"},{"key":"83740_CR27","first-page":"365","volume":"9","author":"EC Lerner","year":"2002","unstructured":"Lerner, E. C. & Smithgall, T. E. SH3-dependent stimulation of Src-family kinase autophosphorylation without tail release from the SH2 domain in vivo. Nat. Struct. Biol. 9, 365\u2013369 (2002).","journal-title":"Nat. Struct. Biol."},{"key":"83740_CR28","doi-asserted-by":"publisher","first-page":"e105629","DOI":"10.1371\/journal.pone.0105629","volume":"9","author":"JA Moroco","year":"2014","unstructured":"Moroco, J. A. et al. Differential sensitivity of Src-family kinases to activation by SH3 domain displacement. PLoS One 9, e105629 (2014).","journal-title":"PLoS One"},{"key":"83740_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6769-12-1","volume":"12","author":"T Pene-Dumitrescu","year":"2012","unstructured":"Pene-Dumitrescu, T. et al. HIV-1 Nef interaction influences the ATP-binding site of the Src-family kinase, Hck. BMC. Chem. Biol. 12, 1 (2012).","journal-title":"BMC. Chem. Biol."},{"key":"83740_CR30","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1021\/acs.biochem.4c00323","volume":"63","author":"AM Selzer","year":"2024","unstructured":"Selzer, A. M., Alvarado, J. J. & Smithgall, T. E. Cocrystallization of the Src-family kinase Hck with the ATP-site inhibitor A-419259 stabilizes an extended activation loop conformation. Biochemistry 63, 2594\u20132601 (2024).","journal-title":"Biochemistry"},{"key":"83740_CR31","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1177\/2040620711410774","volume":"2","author":"B Avni","year":"2011","unstructured":"Avni, B. & Koren-Michowitz, M. Myeloid sarcoma: current approach and therapeutic options. Ther. Adv. Hematol. 2, 309\u2013316 (2011).","journal-title":"Ther. Adv. Hematol."},{"key":"83740_CR32","doi-asserted-by":"publisher","first-page":"101202","DOI":"10.1016\/j.gore.2023.101202","volume":"47","author":"J Hawthorne","year":"2023","unstructured":"Hawthorne, J. et al. Bilateral adnexal masses: A case report of acute myeloid leukemia presenting with myeloid sarcoma of the ovary and review of literature. Gynecol. Oncol. Rep. 47, 101202 (2023).","journal-title":"Gynecol. Oncol. Rep."},{"key":"83740_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.exphem.2017.02.004","volume":"50","author":"J Ghosh","year":"2017","unstructured":"Ghosh, J. & Kapur, R. Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia. Exp. Hematol. 50, 13\u201321 (2017).","journal-title":"Exp. Hematol."},{"key":"83740_CR34","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1158\/1535-7163.MCT-16-0719","volume":"16","author":"BZ Carter","year":"2017","unstructured":"Carter, B. Z. et al. Focal adhesion kinase as a potential target in AML and MDS. Mol. Cancer Ther. 16, 1133\u20131144 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"83740_CR35","doi-asserted-by":"publisher","first-page":"7312","DOI":"10.1158\/0008-5472.CAN-11-1109","volume":"71","author":"M Ren","year":"2011","unstructured":"Ren, M., Qin, H., Ren, R., Tidwell, J. & Cowell, J. K. Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases. Cancer Res. 71, 7312\u20137322 (2011).","journal-title":"Cancer Res."},{"key":"83740_CR36","doi-asserted-by":"crossref","unstructured":"Naser, R., Aldehaiman, A., Diaz-Galicia, E. & Arold, S.T. Endogenous control mechanisms of FAK and PYK2 and their relevance to cancer development. Cancers (Basel) 10 (2018).","DOI":"10.20944\/preprints201805.0125.v1"},{"key":"83740_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130692","volume":"10","author":"S Charmsaz","year":"2015","unstructured":"Charmsaz, S. et al. EphA2 is a therapy target in EphA2-positive leukemias but is not essential for normal hematopoiesis or leukemia. PLoS One 10, e0130692 (2015).","journal-title":"PLoS One"},{"key":"83740_CR38","doi-asserted-by":"publisher","first-page":"730400","DOI":"10.3389\/fcell.2021.730400","volume":"9","author":"F Hao","year":"2021","unstructured":"Hao, F., Wang, C., Sholy, C., Cao, M. & Kang, X. Strategy for leukemia treatment targeting SHP-1,2 and SHIP. Front. Cell Dev. Biol. 9, 730400 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"83740_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.111934","volume":"390","author":"M Deng","year":"2020","unstructured":"Deng, M. et al. Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis. Exp. Cell Res. 390, 111934 (2020).","journal-title":"Exp. Cell Res."},{"key":"83740_CR40","doi-asserted-by":"publisher","first-page":"215593","DOI":"10.1016\/j.canlet.2022.215593","volume":"535","author":"M Artemenko","year":"2022","unstructured":"Artemenko, M., Zhong, S. S. W., To, S. K. Y. & Wong, A. S. T. p70 S6 kinase as a therapeutic target in cancers: More than just an mTOR effector. Cancer Lett. 535, 215593 (2022).","journal-title":"Cancer Lett."},{"key":"83740_CR41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-016-0264-3","volume":"9","author":"Y Gao","year":"2016","unstructured":"Gao, Y. et al. Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia. J. Hematol. Oncol. 9, 36 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"83740_CR42","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1177\/2040620715571077","volume":"6","author":"JM Brandwein","year":"2015","unstructured":"Brandwein, J. M. Targeting polo-like kinase 1 in acute myeloid leukemia. Ther. Adv. Hematol. 6, 80\u201387 (2015).","journal-title":"Ther. Adv. Hematol."},{"key":"83740_CR43","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/s41375-023-01904-1","volume":"37","author":"YL Shao","year":"2023","unstructured":"Shao, Y. L. et al. HIF1alpha-mediated transactivation of WTAP promotes AML cell proliferation via m(6)A-dependent stabilization of KDM4B mRNA. Leukemia 37, 1254\u20131267 (2023).","journal-title":"Leukemia"},{"key":"83740_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exphem.2023.05.005","volume":"124","author":"LD Boila","year":"2023","unstructured":"Boila, L. D. & Sengupta, A. Unifying targeted therapy for leukemia in the era of PARP inhibition. Exp. Hematol. 124, 1\u201314 (2023).","journal-title":"Exp. Hematol."},{"key":"83740_CR45","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1124\/mol.115.098012","volume":"88","author":"T Teo","year":"2015","unstructured":"Teo, T. et al. Pharmacologic inhibition of MNKs in acute myeloid leukemia. Mol. Pharmacol. 88, 380\u2013389 (2015).","journal-title":"Mol. Pharmacol."},{"key":"83740_CR46","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1182\/blood-2016-02-698704","volume":"128","author":"EM Kosciuczuk","year":"2016","unstructured":"Kosciuczuk, E. M. et al. Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo. Blood 128, 410\u2013414 (2016).","journal-title":"Blood"},{"key":"83740_CR47","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/15384047.2015.1016662","volume":"16","author":"ZH Liu","year":"2015","unstructured":"Liu, Z. H., Dai, X. M. & Du, B. Hes1: a key role in stemness, metastasis and multidrug resistance. Cancer Biol. Ther. 16, 353\u2013359 (2015).","journal-title":"Cancer Biol. Ther."},{"key":"83740_CR48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/bs.apcsb.2022.11.008","volume":"135","author":"Nilmani","year":"2023","unstructured":"Nilmani, et al. CDK regulators-Cell cycle progression or apoptosis-scenarios in normal cells and cancerous cells. Adv. Protein Chem. Struct. Biol. 135, 125\u2013177 (2023).","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"83740_CR49","doi-asserted-by":"crossref","unstructured":"Sima, L.E., Matei, D. & Condello, S. The outside-in journey of tissue transglutaminase in cancer. Cells 11 (2022).","DOI":"10.3390\/cells11111779"},{"key":"83740_CR50","doi-asserted-by":"crossref","unstructured":"Ogana, H. A. et al. Targeting integrins in drug-resistant acute myeloid leukaemia. Br. J Pharmacol. (2023).","DOI":"10.1111\/bph.16149"},{"key":"83740_CR51","doi-asserted-by":"crossref","unstructured":"Wang, Q. & Yang, H. S. The role of Pdcd4 in tumour suppression and protein translation. Biol Cell (2018).","DOI":"10.1111\/boc.201800014"},{"key":"83740_CR52","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41467-020-20491-8","volume":"12","author":"T Oki","year":"2021","unstructured":"Oki, T. et al. Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML. Nat. Commun. 12, 245 (2021).","journal-title":"Nat. Commun."},{"key":"83740_CR53","doi-asserted-by":"publisher","first-page":"19455","DOI":"10.1038\/s41598-019-55934-w","volume":"9","author":"D Naci","year":"2019","unstructured":"Naci, D., Berrazouane, S., Barabe, F. & Aoudjit, F. Cell adhesion to collagen promotes leukemia resistance to doxorubicin by reducing DNA damage through the inhibition of Rac1 activation. Sci. Rep. 9, 19455 (2019).","journal-title":"Sci. Rep."},{"key":"83740_CR54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.exphem.2020.09.189","volume":"92","author":"LD Boila","year":"2020","unstructured":"Boila, L. D. & Sengupta, A. Evolving insights on histone methylome regulation in human acute myeloid leukemia pathogenesis and targeted therapy. Exp. Hematol. 92, 19\u201331 (2020).","journal-title":"Exp. Hematol."},{"key":"83740_CR55","doi-asserted-by":"crossref","unstructured":"Wagstaff, M., Coke, B., Hodgkiss, G. R. & Morgan, R. G. Targeting beta-catenin in acute myeloid leukaemia: Past, present, and future perspectives. Biosci. Rep. 42 (2022).","DOI":"10.1042\/BSR20211841"},{"key":"83740_CR56","doi-asserted-by":"publisher","first-page":"873903","DOI":"10.3389\/fonc.2022.873903","volume":"12","author":"X Wu","year":"2022","unstructured":"Wu, X., Ye, W. & Gong, Y. The role of RNA methyltransferase METTL3 in normal and malignant hematopoiesis. Front. Oncol. 12, 873903 (2022).","journal-title":"Front. Oncol."},{"key":"83740_CR57","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.blre.2017.11.006","volume":"32","author":"L Herschbein","year":"2018","unstructured":"Herschbein, L. & Liesveld, J. L. Dueling for dual inhibition: Means to enhance effectiveness of PI3K\/Akt\/mTOR inhibitors in AML. Blood Rev. 32, 235\u2013248 (2018).","journal-title":"Blood Rev."},{"key":"83740_CR58","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00018-015-2108-7","volume":"73","author":"Y Hu","year":"2016","unstructured":"Hu, Y. & Li, S. Survival regulation of leukemia stem cells. Cell Mol. Life Sci. 73, 1039\u20131050 (2016).","journal-title":"Cell Mol. Life Sci."},{"key":"83740_CR59","doi-asserted-by":"publisher","first-page":"eabo6891","DOI":"10.1126\/scitranslmed.abo6891","volume":"14","author":"GP Sullivan","year":"2022","unstructured":"Sullivan, G. P., Flanagan, L., Rodrigues, D. A. & Ni Chonghaile, T. The path to venetoclax resistance is paved with mutations, metabolism, and more. Sci. Transl. Med. 14, eabo6891 (2022).","journal-title":"Sci. Transl. Med."},{"key":"83740_CR60","doi-asserted-by":"publisher","first-page":"6885","DOI":"10.1182\/blood-2010-10-315721","volume":"117","author":"S Elf","year":"2011","unstructured":"Elf, S. et al. p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia. Blood 117, 6885\u20136894 (2011).","journal-title":"Blood"},{"key":"83740_CR61","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/14728214.2017.1330885","volume":"22","author":"A Abou Zahr","year":"2017","unstructured":"Abou Zahr, A. & Borthakur, G. Emerging cell cycle inhibitors for acute myeloid leukemia. Expert Opin. Emerg. Drugs 22, 137\u2013148 (2017).","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"83740_CR62","doi-asserted-by":"publisher","first-page":"101291","DOI":"10.1016\/j.jbc.2021.101291","volume":"297","author":"LM Gagne","year":"2021","unstructured":"Gagne, L. M. et al. Tyrosine phosphorylation of DEPTOR functions as a molecular switch to activate mTOR signaling. J. Biol. Chem. 297, 101291 (2021).","journal-title":"J. Biol. Chem."},{"key":"83740_CR63","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/s41388-021-02092-x","volume":"41","author":"E Aponte","year":"2022","unstructured":"Aponte, E. et al. Regulation of Src tumor activity by its N-terminal intrinsically disordered region. Oncogene 41, 960\u2013970 (2022).","journal-title":"Oncogene"},{"key":"83740_CR64","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/bjh.18996","volume":"203","author":"F Severin","year":"2023","unstructured":"Severin, F. et al. Focal adhesion kinase activation by calcium-dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness. Br. J. Haematol. 203, 224\u2013236 (2023).","journal-title":"Br. J. Haematol."},{"key":"83740_CR65","doi-asserted-by":"crossref","unstructured":"Comenge, J. et al. Multimodal cell tracking from systemic administration to tumour growth by combining gold nanorods and reporter genes. Elife 7 (2018).","DOI":"10.7554\/eLife.33140"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83740-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83740-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83740-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:03:36Z","timestamp":1735949016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83740-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["83740"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-83740-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"174"}}